Research and Markets: Global HER-2 Positive Breast Cancer Market 2015-2019 with Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Sanofi Dominating

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/hlsf79/global_her2) has announced the addition of the "Global HER-2 Positive Breast Cancer Market 2015-2019" report to their offering.

The analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

Increased public awareness is a key trend, which is expected to positively impact the growth of the market. Awareness and screening programs can help diagnose potential cases of breast cancer that would otherwise remain undetected till the late stages.

According to the report, the increase in the prevalence of breast cancer is a major driver, which is expected to affect the overall market growth in the next five years. With the growing incidence of breast cancer, more and more people are opting for the treatment regimen.

Further, the report states that late-stage diagnosis and expensive screening techniques pose a challenge to the market and have a negative impact on the market growth. Expensive screening techniques like mammography screening lead to poor response from patients.

Key Vendors

  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi

Other Prominent Vendors

  • Actavis
  • Array BioPharma
  • Biocad
  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • DARA BioSciences
  • EddingPharm
  • Eisai
  • Galena Biopharma
  • Halozyme Therapeutics
  • Hospira
  • Mylan
  • Oncothyreon
  • Pfizer
  • ProStrakan
  • Puma Biotechnology
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva Pharmaceutical

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Introduction
  6. Disease Overview
  7. Pipeline Analysis
  8. Market Landscape
  9. Market Segmentation by Type of Therapy
  10. Market Segmentation by Molecule Type
  11. Market Segmentation by Route of Administration
  12. Geographical Segmentation
  13. Buying Criteria
  14. Market Growth Drivers
  15. Drivers and their Impact
  16. Market Challenges
  17. Impact of Drivers and Challenges
  18. Market Trends
  19. Trends and their Impact
  20. Vendor Landscape
  21. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/hlsf79/global_her2

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Breast Cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Breast Cancer